# Early Detection Early Cure

NPC GOLD™ is a non-invasive screening and monitoring blood test for nasopharyngeal cancer (NPC) that is developed and validated in Singapore¹. NPC screening is made easy for earlier treatment and higher survival rates¹.²,³.

# Sensitive

Targets the highly stable CpG islands of *Bam*HI-W repetitive sequences in the EBV genome for higher test sensitivity<sup>1,4</sup>, improving detection for Stage I and II NPC.

#### Superior detection rate for BamHI-W CpG DNA qPCR<sup>1,4</sup>



Data from National Cancer Centre Singapore

# Specific

Targets the NPC specific 143bp EBV fragments<sup>1,4</sup>, reducing false positives<sup>5</sup>. Blood collection in Streck Tube reduces B-cell lysis that affects plasma circulating EBV.

# How NPC GOLD™ helps

#### **Positive result**

It is recommended to repeat NPC GOLD™ test 4 weeks later to determine persistent positivity³. If the result is again positive, the patient should undergo further evaluation for NPC.

#### **Negative result**

Annual screening is recommended for early detection based on published cohort follow-up data<sup>3</sup>.

#### **Technology**

Real-time quantitative polymerase chain reaction (qPCR)

#### **Target**

BamHI-W CpG islands in Epstein-Barr Virus (EBV)

#### Sample Requirement

Blood in 1 Streck Tube (9mL)

### Turnaround time

3-5 working days

Sensitivity

89%

Specificity

100%

**Limit of Detection** 

50 IU/ mL

 Vo, J. H. et al. Scientific Reports. 2016;6(f):1-9
 Howlader, N. et al. SEER Cancer Statistics Reviet 1975-2017, National Cancer Institute.
 Chan, K. A. et al. N Engl. J Med. 2017;377(6):513-52
 Tan, M.H. & Vo, J. H. 2016. PCT/SG2016/050611
 Lam, W.J. et al. PNAS. 2018;115(22):E5115-E5124

**LUCENCE** 

# Customer support: +65 6592 5102 sales.asean@lucence.com

lucence.com